Stock Report

All about this stock under one free report Last Updated: 11-Sep-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Immunoprecise Antibodies (IPA) Key Ratios

Stock Card factsheet share-fund-plan-icon

$1.77

up-down-arrow $-0.30 (-14.49%)

As on 02-Oct-2025 09:30EDT

Market cap

info icon

$96 Mln

Revenue (TTM)

info icon

$25 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

5.6

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 13.49 8.08 0.01 8.19 11.77
EBIT 92.20 50.65 -144.99 -159.25 -247.87
Net Profit 89.96 88.02 -12.97 -42.46 -232.67
EPS -- -- -- -- --
Book Value -- -- -- -- --
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsApr-25Apr-24Apr-23
EBIT-Margin info -129.90-99.95-138.56-116.99-134.15
Net Margin info ----------
Return on equity info -68.08-49.98-105.08-59.26-39.91
Return on Capital info -52.29-39.88-71.45-48.24-37.17
Return on Assets info -42.79-32.95-57.90-39.44-31.01
Debt to Equity (x) info ----0.570.400.13

Profitability

View Detailed Peer Comparison

ROCE

-71.45

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
Apr-25
Apr-24
Apr-23
Apr-22
Apr-21
Immunoprecise Antibodies (IPA)
-71.45
-48.24
-37.17
-24.18
-18.36
Peer Median
--
--
--
--
--
ROE

-105.08

--

Profit after tax / Average Net worth * 100

Company Name
Apr-25
Apr-24
Apr-23
Apr-22
Apr-21
Immunoprecise Antibodies (IPA)
-105.08
-59.26
-39.91
-25.28
-20.39
Peer Median
--
--
--
--
--
ROA

-57.90

--

Profit after tax / Average Total assets * 100

Company Name
Apr-25
Apr-24
Apr-23
Apr-22
Apr-21
Immunoprecise Antibodies (IPA)
-57.90
-39.44
-31.01
-20.83
-15.58
Peer Median
--
--
--
--
--
EBIT Margin

-138.56

--

Operating profit (EBIT) / Net Sales * 100

Company Name
Apr-25
Apr-24
Apr-23
Apr-22
Apr-21
Immunoprecise Antibodies (IPA)
-138.56
-116.99
-134.15
-81.40
-28.65
Peer Median
--
--
--
--
--
Net Margin

-123.30

--

Net profit / Total Income (Net sales plus other income) * 100

Company Name
Apr-25
Apr-24
Apr-23
Apr-22
Apr-21
Immunoprecise Antibodies (IPA)
-123.30
-110.85
-128.53
-86.29
-40.98
Peer Median
--
--
--
--
--

Growth

View Detailed Peer Comparison

Revenue Growth

0.00

--

Year on year growth in net sales

Company Name
Apr-25
Apr-24
Apr-23
Apr-22
Apr-21
Immunoprecise Antibodies (IPA)
0.00
0.19
0.07
0.08
0.27
Peer Median
--
--
--
--
--
EBIT Growth

-18.44

--

Year on year growth in operating profit (EBIT)

Company Name
Apr-25
Apr-24
Apr-23
Apr-22
Apr-21
Immunoprecise Antibodies (IPA)
-18.44
-3.47
-75.87
-207.15
-33.09
Peer Median
--
--
--
--
--
Net Profit Growth

-11.25

--

Year on year growth in profit after tax

Company Name
Apr-25
Apr-24
Apr-23
Apr-22
Apr-21
Immunoprecise Antibodies (IPA)
-11.25
-2.32
-58.96
-127.64
-48.37
Peer Median
--
--
--
--
--

Solvency

View Detailed Peer Comparison

Debt to Equity

0.57

--

Total debt / Net worth

Company Name
Apr-25
Apr-24
Apr-23
Apr-22
Apr-21
Immunoprecise Antibodies (IPA)
0.57
0.40
0.13
0.03
0.06
Peer Median
--
--
--
--
--
Short term debt to equity ratio

0.08

--

(Short term borrowings / Net worth)

Company Name
Apr-25
Apr-24
Apr-23
Apr-22
Apr-21
Immunoprecise Antibodies (IPA)
0.08
0.05
0.02
0.03
0.02
Peer Median
--
--
--
--
--
Current Ratio

2.08

--

Current Assets / Current Liabilities and Provisions

Company Name
Apr-25
Apr-24
Apr-23
Apr-22
Apr-21
Immunoprecise Antibodies (IPA)
2.08
1.41
2.84
4.05
8.05
Peer Median
--
--
--
--
--
Quick Ratio

1.85

--

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
Apr-25
Apr-24
Apr-23
Apr-22
Apr-21
Immunoprecise Antibodies (IPA)
1.85
1.15
2.49
3.87
7.85
Peer Median
--
--
--
--
--
Interest Coverage

-115.95

--

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
Apr-25
Apr-24
Apr-23
Apr-22
Apr-21
Immunoprecise Antibodies (IPA)
-115.95
-1,509.68
-924.07
-185.45
-5.95
Peer Median
--
--
--
--
--

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

19.60

--

Debtors outstanding / Net Sales * 100

Company Name
Apr-25
Apr-24
Apr-23
Apr-22
Apr-21
Immunoprecise Antibodies (IPA)
19.60
16.59
21.36
17.60
23.00
Peer Median
--
--
--
--
--
Asset Turnover

0.47

--

Sales / Average Total Assets

Company Name
Apr-25
Apr-24
Apr-23
Apr-22
Apr-21
Immunoprecise Antibodies (IPA)
0.47
0.36
0.24
0.24
0.38
Peer Median
--
--
--
--
--
Receivable days

66.09

--

Average Debtors / Sales * 365

Company Name
Apr-25
Apr-24
Apr-23
Apr-22
Apr-21
Immunoprecise Antibodies (IPA)
66.09
63.18
69.14
71.00
79.31
Peer Median
--
--
--
--
--
Inventory Days

70.47

--

Average Inventory / Sales * 365

Company Name
Apr-25
Apr-24
Apr-23
Apr-22
Apr-21
Immunoprecise Antibodies (IPA)
70.47
61.52
73.74
61.43
57.95
Peer Median
--
--
--
--
--
Payable days

155.71

--

Average Creditors / Cost of goods sold * 365

Company Name
Apr-25
Apr-24
Apr-23
Apr-22
Apr-21
Immunoprecise Antibodies (IPA)
155.71
96.05
128.43
114.66
77.33
Peer Median
--
--
--
--
--
Cash Conversion Cycle

-19.15

--

Receivable Days + Inventory Days - Payable Days

Company Name
Apr-25
Apr-24
Apr-23
Apr-22
Apr-21
Immunoprecise Antibodies (IPA)
-19.15
28.65
14.45
17.76
59.94
Peer Median
--
--
--
--
--
loading...
loading...